Services on Demand
- Cited by Google
- Similars in SciELO
- Similars in Google
Print version ISSN 0074-0276
Mem. Inst. Oswaldo Cruz vol.106 no.5 Rio de Janeiro Aug. 2011
Mariana GandiniI; Sonia Regina Nogueira Ignacio ReisI; Amanda Torrentes CarvalhoI; Elzinandes Leal AzeredoI; Marcos da Silva FreireII; Ricardo GallerII; Claire Fernandes KubelkaI, +
ILaboratório de Imunologia Viral, Instituto Oswaldo Cruz
IIDepartamento de Desenvolvimento Tecnológico, Instituto de Tecnologia em Imunobiológicos-Fiocruz, Av. Brasil 4365, 21045-900 Rio de Janeiro, RJ, Brasil
Flaviviruses cause severe acute febrile and haemorrhagic infections, including dengue and yellow fever and the pathogenesis of these infections is caused by an exacerbated immune response. Dendritic cells (DCs) are targets for dengue virus (DENV) and yellow fever virus (YF) replication and are the first cell population to interact with these viruses during a natural infection, which leads to an induction of protective immunity in humans. We studied the infectivity of DENV2 (strain 16681), a YF vaccine (YF17DD) and a chimeric YF17D/DENV2 vaccine in monocyte-derived DCs in vitro with regard to cell maturation, activation and cytokine production. Higher viral antigen positive cell frequencies were observed for DENV2 when compared with both vaccine viruses. Flavivirus-infected cultures exhibited dendritic cell activation and maturation molecules. CD38 expression on DCs was enhanced for both DENV2 and YF17DD, whereas OX40L expression was decreased as compared to mock-stimulated cells, suggesting that a T helper 1 profile is favoured. Tumor necrosis factor (TNF)-α production in cell cultures was significantly higher in DENV2-infected cultures than in cultures infected with YF17DD or YF17D/DENV. In contrast, the vaccines induced higher IFN-α levels than DENV2. The differential cytokine production indicates that DENV2 results in TNF induction, which discriminates it from vaccine viruses that preferentially stimulate interferon expression. These differential response profiles may influence the pathogenic infection outcome.
Key words: cytokines - dendritic cells - dengue virus - yellow fever vaccine - flavivirus
Flaviviruses are arthropod-borne viruses that may cause severe acute infectious diseases, such as dengue fever and yellow fever (YF). Dengue fever is the most important arthropod-borne emerging viral disease in tropical countries due to high morbidity and increased risk of mortality (Gubler 2002). The YF17DD vaccine induces long-lasting immunity, similar to wild viruses (Monath 2001, Halstead 2007). For dengue fever, a chimeric YF/dengue vaccine (ChimeriVaxTM technology) is currently being tested in clinical trials (Guy et al. 2010). Both dengue and YF wild viruses can induce a broad spectrum of clinical manifestations from asymptomatic to severe clinical features, the latter of which is characterised by haemorrhaic manifestations and shock syndrome, which are associated with vascular permeability and leakage. Cytokines play a key role in the generation of these physiopathological processes (Geisbert & Jahrling 2004). Moreover, the occurrence of rare fatal cases and adverse clinical manifestations has been associated with the YF vaccine (Vasconcelos et al. 2001, Silva et al. 2010).
Several cytokines have been associated with disease severity in patients. For dengue fever, tumor necrosis factor (TNF)-α (Hober et al. 1993, Braga et al. 2001), interleukin (IL)-10 (Green et al. 1999, Azeredo et al. 2001), IL-6 (Nguyen et al. 2004), macrophage inhibitory factor (Chen et al. 2006, Assuncao-Miranda et al. 2010) and interferon (IFN)-Γ (Bozza et al. 2008), among others (Srikiatkhachorn & Green 2010), have been reported. Chemokines also have an important role in pathogenesis. For example, IP-10/CXCL-10 was found to be elevated in dengue haemorrhagic fever (DHF) (Fink et al. 2007) and MCP-1/CCL-2 (Lee et al. 2006), while MIP-1β/CCL-4 is associated with a good prognosis (Bozza et al. 2008). Elevated serum levels of IL-6, IL-8, TNF-α, MCP-1, IL-1 receptor agonist (Ra) and IL-10 were observed in fatal YF cases when compared with non-fatal cases (Bae et al. 2008). Finally, in vaccinated individuals, high levels of IP-10, IL-1β, TNF-α, IFN-Γ and IL-10 were detected (Querec et al. 2009, Silva et al. 2011).
Monocytes, macrophages and dendritic cells (DCs) are the main targets for viruses involved in vascular permeability induction (Schnittler & Feldmann 2003, Clyde et al. 2006). Mononuclear phagocytes become activated by virus, which induces synthesis and release of cytokines (e.g., TNF-α, IL-6, IL-1β, IFN-α/β and IL-10) and chemokines (e.g., IL-8, MIP-1α and MCP-1). These factors produced by in vitro infected cells are known to induce alterations in the endothelium, which leads to the imbalance of fluid between the intra and extra-vascular areas of tissues and ultimately culminates in shock (Srikiatkhachorn 2009). Coagulation features that occur during dengue fever may be linked to mononuclear phagocyte and endothelial cell activation because pro-inflammatory cytokines interfere with the activation of coagulation factors (Suharti et al. 2002).
After virus infection, DCs become activated and mature. During maturation processes, DCs usually upregulate co-stimulatory molecules, such as CD80, CD86, CD83, CD40, CD38 and OX40L (Quah & O'Neill 2005). These molecules may be involved in the polarisation of T helper (Th) cells into either Th-1 or Th-2 subsets. CD38, IFN-Γ and IL-12p70 are associated with Th-1 responses (Frasca et al. 2006). On the other hand, OX40L expression on DCs contributes to Th-2 polarisation (Delespesse et al. 1999). Mature DCs are able to activate T lymphocytes and drive the type of the immune response (Lanzavecchia & Sallusto 2004). It is believed that T cell activation in patients with severe dengue leads to T cell responses with less avidity for serotype-specific responses than mild dengue, resulting in a pathologic cytokine storm with limited antiviral responses (Duangchinda et al. 2010).
The aim of this investigation was to study the innate immune response induced in vitro by distinct flaviviruses. We selected a pathogenic strain of dengue virus (DENV) 2 (16681) originated from a DHF SE Asian case and the Brazilian YF17DD, which is known for its protective properties with minimal deleterious effects. A chimeric YF17D/DENV2 vaccine virus (Caufour et al. 2001) was assayed as well. We report for the first time that flaviviruses induce the expression of the DC maturation marker CD38 and downregulate OX40L, suggesting that a Th-1 response has been generated. Additionally, differential TNF-α and IFN-α expression by DCs infected with DENV and vaccine YF17DD or 17D/DENV2 viruses are discussed, with regard to their possible influence on pathogenicity and virus clearance.
MATERIALS AND METHODS
Virus strain, cell cultures, virus stock preparation and titration - DENV2 (strain Thailand/16681/1984) was provided by Dr SB Halstead (Naval Medical Research Centre, USA). YF strain 17DD is the live attenuated virus used in the YF vaccine manufactured by Bio-Manguinhos, Oswaldo Cruz Foundation, Rio de Janeiro (RJ), Brazil (Post et al. 1991). For virus stock preparation, Vero cells (CCL 81, ATCC) were maintained in 199 medium with Earle's salts buffered with sodium bicarbonate and supplemented with 5% foetal bovine serum (FCS) and antibiotics (Gibco, Invitrogen). Viral stock was prepared by flavivirus infection of a Vero cell monolayer in T175 flasks. When cytopathic effects were observed seven days later, the supernatant was harvested and supplemented with 30% FCS and aliquots were frozen at -70ºC. Virus stock was titrated by serial dilution cultures in microtitre plates and detected by immunofluorescence as previously described (Miagostovich et al. 1993). An uninfected flask was also maintained and the supernatant was collected to be used as a mock inoculum. A mock infection was included in each experiment.
A set of experiments was performed using the chimeric virus YF/DENV2 strain 44/3. This virus contains the pre-M and E genes from DENV2 strain New Guinea C, with the carboxyl end of protein E (E261-E495 amino acids) that belongs to the Brazilian strain 44/2 (Caufour et al. 2001). This chimeric virus elicits a protective immune response against DENV challenge both in mice and Rhesus monkeys, which includes neutralising antibodies (Caufour et al. 2001, Galler et al. 2005).
Virus titre was calculated as 50% tissue culture infectious dose (TCID50/mL). However, when the virus was compared with the chimeric virus 44/3 (Fig. 1), all three viruses were titrated by the plaque-forming assay as described before (Galler et al. 2005).
Human monocyte-derived DCs (MoDCs) - Human peripheral blood was obtained from University Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro (UFRJ), RJ. Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors' buffy coats by centrifugation on a density gradient (400 g for 30 min in Ficoll-Paque Plus, Amersham Biosciences Corp), as described previously (Reis et al. 2007). Cells were resuspended at 106 cells/mL in RPMI 1640 supplemented with 200 mM glutamine, 100 U/mL penicillin and 10 mg/mL streptomycin (Gibco, Invitrogen) and incubated at 37ºC under a humid atmosphere with 5% CO2. The cells where then allowed to adhere to uncoated polystyrene flasks (150 cm3) for 90 min to enrich for monocytes. Non-adherent cells were gently removed by washing and the adherent cells were detached by mechanical cell harvesting with cell scrapers in cold cell culture medium. Cell viability was verified in the cultures by Trypan blue exclusion and was > 95%. Enriched monocytes were suspended in RPMI 1640 medium supplemented with 10% FCS, 500 U/mL human rGM-CSF and 500 U/mL rIL-4 (Peprotech) and seeded at 1 x 106 cells/mL on 24-well plates (Nunc, Thermo Fisher Scientific). Cytokines were added every other day for six days. The appropriate phenotype of DC differentiation was confirmed before each experiment by flow cytometry.
Infection of human MoDCs by flaviviruses - After a six-day cell differentiation period, MoDCs were incubated with YF17DD, a dose equivalent to that used for DENV2 (2.5 x 105 TCID50/mL), a dose five times more concentrated or cell culture supernatant as mock treatment diluted inoculum (500 µL). This compensation for the infectivity of different flavivirus has also been previously reported (Youn et al. 2010). For experiments comparing the YF17DD, DENV2 and YF17D/DENV2 viruses, the multiplicity of infection (MOI) was 4 (4x106 plaque-forming unit/106 cells).
After three-hour incubation for adsorption at 37ºC under humid atmosphere with 5% CO2, culture supernatants were replaced with medium containing 10% FCS and further incubated for 24-120 h. Each different parameter was set up in triplicate wells. After infection, supernatants were collected at defined intervals and stored at -70ºC until cytokine measurement and cells were recovered for viral antigen and surface marker determination by flow cytometry.
Detection of viral antigen and specific co-stimulatory markers by flow cytometry in human MoDCs - Cells were harvested by vigorous pipetting using cold wash buffer [phosphate-buffered saline (PBS) pH 7.4, 1% bovine serum albumin (BSA) (Sigma) and 0.1% sodium azide] and were resuspended at 1 x 106 cells/microtube. The cells were then centrifuged (260 g, 7 min) and washed once more with wash buffer. Single or double cell labelling of infected and uninfected cultures was performed. For surface labelling, the cells were blocked with 5% heat-inactivated human plasma in wash buffer for 30 min at 4ºC and further incubated for 30 min with anti-human CD1a-PE (Iotest Immunotech, Beckman Coulter Inc, Brea, CA, USA), DC-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN)-FITC (R&D Systems), CD14-PE (DakoCytomation), HLA-DR,DP,DQ-FITC (Dako Cytomation), CD80-FITC (Iotest Immunotech), CD38-FITC (Caltag, Invitrogen) or OX40L-PE (BD Biosciences Pharmingen). Matching isotype antibodies were used as negative controls. The cells were washed and subsequently fixed with 2% paraformaldehyde. Intracellular staining was performed according to previously described methods (Neves-Souza et al. 2005), with slight modifications. Briefly, the cells were fixed with cold 2% paraformaldehyde in PBS for 20 min and, after centrifugation, the membranes were permeabilised with 0.15% saponin in wash buffer. The cells were blocked with 5% heat-inactivated human plasma in wash buffer for 30 min at 4ºC. Primary monoclonal antibody incubation was performed with anti-Dengue Complex (Chemicon, Millipore, Billerica, MA, USA), anti-Yellow Fever (Biogenesis, AbD Serotec) or an isotype-matched antibody diluted in wash buffer containing 0.15% saponin for 60 min at 4ºC. The cells were washed once with wash buffer and further incubated with secondary anti-mouse labelled with Alexa Fluor-488 (Molecular Probes, Invitrogen) for 30 min at 4ºC. The cells were acquired (10,000 events for DC-SIGN positive gate) on a FACSCalibur flow cytometer (BD Biosciences). Analysis was performed using FlowJo (TreeStar Inc, Ashland, OR, USA) or Summit (Dako Automation).
Enzyme-linked immunosorbent assay (ELISA) for TNF-α - ELISA plates (MaxiSorp, Nunc) were coated overnight at room temperature (RT) with 1 µg/mL at 100 µL/well of rabbit anti-human TNF-α antibody provided in the Human TNF-α ELISA Development Kit (Peprotech). The plates were washed with 0.05% Tween 20 (Sigma) in PBS and were incubated with 1% BSA in PBS at 250 µL/well for 90 min at RT. The samples and standards were added in duplicate at 100 µL/well and the plates were incubated overnight at 4ºC. Subsequent incubation with 0.25 µg/mL at 100 µL/well of biotinylated detection antibody for TNF-α was performed for 120 min at RT. This procedure was followed by a 30-min incubation with streptavidin-peroxidase (Streptavidin, Zymed, Invitrogen) at 1:2,000 dilution with 100 µL/well. Tetramethylbenzidine (KPL Inc) was added and the plates were read at 630 nm after 15-min incubation.
Cytokine detection in cell culture supernatant by multiplex microbead immunoassay - A multiplex biometric immunoassay, which contains fluorescent microspheres conjugated with a monoclonal antibody specific for a target protein, was employed for cytokine and chemokine measurement according to the manufacturer's instructions (Upstate, Millipore) as described previously (Reis et al. 2007). Measured cytokines including the following: IFN-α, IL-6, IL-1Ra, IL-10, MCP-1/CCL-2, MIP-1β/CCL-4, IP-10/CXCL-10 and RANTES/CCL-5. Briefly, cell culture supernatants (50 µL) were incubated overnight at 4ºC with pooled antibody-coupled beads in bottom filter plates (Millipore). The complexes were washed and incubated with pooled biotinylated detection antibodies for 90 min at RT. Then, streptavidin-phycoerythrin was added for 30 min at RT prior to assessing cytokine concentration titres. A broad range (1.95-8,000 pg/mL) of concentrated human recombinant cytokines, provided by the vendor, was used to establish standard curves to maximise assay sensitivity and dynamic range. Cytokine levels were determined with a multiplex array reader from Luminex Instrumentation System (Bio-Plex Workstation from Bio-Rad Laboratories). The analyte concentration was calculated by the software provided by the manufacturer (Bio-Plex Manager Software), which provided a regression analysis to derive the equation for cytokine concentration prediction in cell culture samples.
Ethics - Procedures performed in this work were approved by the Ethical Committee of the Fiocruz, Brazilian Health Ministry (recognised by the Brazilian National Ethics Committee) (111/00 and CAAE-0064.0.011.000-07).
Statistical analyses - Data were first tested for normality with Prism version 4.0 for Windows (GraphPad Software). Flow cytometry data exhibited normal distributions, while normality was not detected for cytokine and chemokine production. To determine whether there were significant differences in viral antigen expression, data values were subjected to one-way analysis of variance followed by Tukey's multiple comparison test. Data from cytokine and chemokine assessments were submitted to a Wilcoxon signed rank test.
DENV2 and YF17DD infection kinetics in human MoDCs - Considering that DCs have been described as targets for DENV and YF vaccines (Barba-Spaeth et al. 2005, Neves-Souza et al. 2005) we investigated these host-virus interactions in detail. MoDCs that originated from healthy human PBMC donors exhibited characteristic downregulation of CD14 (1.8 ± 0.9%) and upregulation of DC-SIGN (75 ± 5%) and CD1a (54 ± 6%). These cells expressed low levels of CD80 and less HLA-DR,P,Q than MoDCs that were stimulated with bacterial lipopolysaccharides and human IFN-Γ (data not shown). The MoDCs exhibit characteristics of immature DCs, which have the ability to perform endocytosis and capture antigens and are more susceptible to virus infection (Steinman & Nussenzweig 2002).
MoDC cultures were incubated with YF17DD vaccine virus at a dose either equivalent to that used for DENV2 (2.5 x 105 TCID50/mL) or with a dose five times more concentrated. Fig. 2A shows histograms obtained by flow cytometry analysis after intracellular viral antigen labelling, representing data from cells incubated with the three different inocula at 24 h after infection. Fig. 1B shows percentages of viral antigen-positive cell (Ag+) rates from 24-72 h post-infection (hpi). Both viruses were able to infect MoDCs, but higher inoculum doses of YF17DD were required to generate similar frequencies of infected cells compared with DENV2. The peak infection rate was detected at 24 hpi, although significant percentages were still detected at 48-72 hpi. Fig. 2C shows viral antigen detection in MoDCs originated from 11 different PBMC donors, confirming that DENV2 is significantly more infectious than YF17DD when the same MOI is used (p < 0.0001). Cells cultured with mock or heat-inactivated inocula contained less than 0.5% positive labelled cells PBMC donors in all assays (data not shown).
Except when mentioned, the assays described below were performed using YF17DD at the higher MOI, which induced similar rates of cell infection when compared to DENV2.
CD38 and OX40L activation/maturation markers are regulated during MoDCs infection with DENV2 and YF17DD - DCs interact with pathogens or exogenous molecules and undergo activation and maturation processes, resulting in reduced antigen processing capacity and increased expression of co-stimulatory and adhesion molecules. These molecules may induce tissue migration, antigen-specific immunological responses and Th polarisation (Quah & O'Neill 2005, Wallet et al. 2005). CD38 is involved in chemotaxis and calcium mobilisation and binds to CD31 on endothelial cells, facilitating DC migration through endothelium (Frasca et al. 2006). It may participate in the Th-1 response, which involves lymphocytes producing IL-12 and IFN-α. On the other hand, OX40L expression on DCs (Ohshima et al. 1997) may contribute to the Th-2 polarisation by enhancing IL-4 and IL-13 induction and suppressing IFN-α after it binds to OX40 on T cells (Ohshima et al. 1998, Delespesse et al. 1999).
MoDCs were cultured with DENV2, YF17DD or mock supernatants. Fig. 3A shows that CD38 was weakly expressed on infected cells but increased when fluorescence intensity virus was present. DC activation occurs between 48-72 hpi (Fig. 3B). MoDCs express OX40L early in infection, but this molecule was downregulated at 48 and 72 hpi (Fig. 3C). This shift is shown in the histograms from flow cytometry data (Fig. 3A), whereas the mock-infected cells remain unchanged and express OX40L.
The ratio of percentages of CD38 and OX40L-expressing cells was calculated for each PBMC donor. In the presence of DENV2, there was an increase from 0.49 ± 0.01 at 24 hpi to 1.90 ± 0.34 at 48 hpi. A similar pattern was observed for the YF17DD-infected cultures, with a ratio of 0.50 ± 0.15 at 24 hpi and one of 1.55 ± 0.03 at 72 hpi. For mock-infected cells this ratio remained below 0.5 (data from 2 cell donors). We therefore observed a change in the CD38 and OX40L balance during infection by both flaviviruses.
Several cytokines and chemokines are present in supernatants of virus-infected MoDCs - Cytokines and chemokines play important roles in dengue physiopathology (Bozza et al. 2008, Noisakran & Perng 2008). Since DCs are one of the main sources for these molecules early in viral infection, we investigated the production of several of them after MoDC infection by DENV2 and YF17DD from 24-120 hpi. We searched for the presence of inflammatory cytokines, chemokines and antiviral molecules that could drive T cell polarisation, either inducing vascular permeability or controlling infection. We detected TNF-α, IFN-α, IL-6, IL-1Ra, IL-10, MIP-1β/CCL-4, MCP-1/CCL-2, IP-10/CXCL-10 and RANTES/CCL-5 in cell culture supernatants. A mock-infected MoDc culture supernatant was also assayed.
Cytokines were detected after infection by both flaviviruses. IL-6 and IL-10 (Fig. 4A, B) were detected in cultured PBMC from seven donors at significant levels (p < 0.5, in a Wilcoxon signed rank test). These factors are known to modulate the immune response (Sabatte et al. 2007). IL-1Ra, the antagonist of the pro-inflammatory cytokine IL-1β and chemotactic factor IP-10 were also increased in most of the donors tested (Fig. 4C, D), although with borderline significance (0.0624 < p < 0.0782; in a Wilcoxon test). RANTES and MCP-1 are both chemokines related to severity of infection (Lee et al. 2006, Pulendran et al. 2008) and were only slightly increased after infection (Fig. 4E, F). However, low donor numbers did not allow us to perform reliable statistical analysis between the two viruses. MIP-1β/CCL-4, which is correlated with non-severe disease, was detected in mock cultures from seven PBMC donors and, apparently, its production was not altered after infection with either virus (data not shown). In vivo, other cells may be responsible for its synthesis and release.
Significant TNF-α amounts were already detected at 24 hpi in the presence of either virus when compared to the mock culture (data not shown), with a peak at 48 hpi and a decline thereafter in most PBMC donors tested (Fig. 5). DENV2 induced the highest TNF-α levels (255 ± 75 pg/mL), which were significantly higher when compared with those produced by YF17DD (121 ± 31 pg/mL) in eight different PBMC donors assayed at 48 hpi (p= 0.0156 in the Wilcoxon test).
In Fig. 6, IFN-α is plotted against viral Ag+ cells during the course of infection in four different PBMC donors. At 24 hpi, IFN-α is already detected in YF17DD-infected MoDCs and at 48 hpi in DENV2-infected MoDCs. Virus load decreases as the IFN-α levels increase. MoDCs from seven donors were assayed side-by-side at 48 h with both viruses and those infected with YF17DD produced significantly higher IFN-α levels (393 ± 139 pg/mL) than those infected with DENV2 (72 ± 29 pg/mL; p = 0.0156 in a Wilcoxon test).
When the ratio of TNF-α and IFN-α levels for each cell donor is calculated, significantly higher indexes were obtained for DENV2 (13 ± 6) than for YF17DD (1.1 ± 0.3; p = 0.0156 in a Wilcoxon test).
As mentioned, data shown in Fig. 4B were generated with higher doses of YF17DD than DENV2 inoculum dose to obtain viral Ag+ cells at the same rates. When YF17DD was inoculated at DENV2 equivalent MOIs (thus resulting in lower infection rates) (Fig. 2), IFN-α levels were 2-10 times higher in YF17DD cultures than those in DENV2. Therefore, the TNF-α vs. IFN-α cytokine imbalance has a different pattern in the two flavivirus studied irrespective of the MOI used.
YF17D/DENV2 vaccine virus infection compared with DENV2 or YF17DD infections - To investigate whether a chimeric dengue target vaccine virus could induce similar responses to the YF17DD vaccine virus, we performed pilot experiments infecting MoDCs with the YF17D/DENV2 vaccine virus. Cell infection rates were lower for the chimeric virus compared with the other two viruses (DENV2 16681 strain and YF17DD) (Fig. 6). IFN-α levels detected in experiments with this chimeric virus were slightly higher than those produced by DENV2, but these differences were not statistically significant (Wilcoxon signed rank test). However, TNF-α levels were significantly higher after DENV2 infection when compared with YF17D/DENV2 infection (p = 0.0313). Therefore, the chimeric vaccine virus apparently displayed a similar cytokine response profile to YF17DD, even though it had lower replication rates.
During either a natural infection or a vaccination, the entry site of flaviviruses into the vertebrate host is the dermis. Langerhans cells were characterised as permissive cells for DENV in vivo replication (Wu et al. 2000). Indeed, DCs have a crucial role in initiating host defence mechanisms; through antigen presentation and cytokine production, they can define the fate of the immunological response (Blanco et al. 2008). Both DENV and YF vaccine viruses are known to infect DCs and monocytes in vitro (Wu et al. 2000, Barba-Spaeth et al. 2005, Reis et al. 2007). We aimed to characterise the similarities and differences between flavivirus infections with distinct virulence patterns that elicit long lasting in vivo immunity (Monath 2001, Halstead 2007).
DC infections with the YF Brazilian vaccine strain 17DD and with YF17D/DENV2 (44/3) chimeric virus were reported here for the first time. The YF17DD vaccine virus infects cells at inoculum doses equivalent to those used for DENV2 (16681 strain) but showed reduced expression of viral antigens within DCs at all time points tested when compared to DENV. Similar results were described for the YF vaccine strain 204, which is poorly infectious compared with DENV (Deauvieau et al. 2007). Other authors used higher MOIs for DENV to obtain the same relative infection level as West Nile virus because these viruses replicate at different rates. They then studied NS1 antigenic expression by flow cytometry analysis (Youn et al. 2010).
DENV sequences from YF17D/DENV2 (44/3) studied here are from the NGC virus. Although our DENV2 originated from strain 16681, NGC and 16681 are very similar with regard to their genome and they belong to the same genotype - SE Asian strains - that characteristically induce the most severe forms of dengue fever (Leitmeyer et al. 1999). We do not intend to compare the virus structures but instead the virulence (pathogenic vs. vaccine).
Virulent YF wild-type or Asibi strains have not been reported to infect DCs, but a few studies compared these viruses with YF17DD during infection in Kupffer or endothelial cells (Khaiboullina et al. 2005, Woodson et al. 2011). Both viruses infect these cells, but the resulting cytokine production is quite different. The virulent YF strains produce a much more intense pro-inflammatory cytokine response (including TNF-α, IL-6, IL-8 and RANTES/CCL5) than the YF vaccine, which produces more IL-10.
During infection by viruses, DCs may undergo several phenotypic changes to become activated and capable of antigen presentation to T lymphocytes. Among these changes is the upregulation of surface markers and soluble molecules related to the polarisation of the T effector cell response. YF17DD immunisation leads to natural killer (NK) cell and monocyte activation (Martins et al. 2008). With respect to DENV and YF17D/DENV chimeric viruses, earlier reports showed that activation molecules, such as CD80, CD86 and CD83, can be upregulated after DC infection (Libraty et al. 2001, Deauvieau et al. 2007, Sun et al. 2009). Co-stimulation molecules, such as CD38, are present in circulating monocytes but are poorly expressed after their differentiation into immature DCs. During the maturation process, CD38 is re-expressed on DCs (Fedele et al. 2004). In the present study, we observed that flavivirus infection favours CD38 expression on DCs. This molecule is involved in cytoplasmatic calcium release, chemotaxis and IFN-Γ production, indicating a role for CD38 in Th-1 polarisation (Frasca et al. 2006).
OX40L expression is a fundamental requirement for optimal induction of primary and memory Th-2 responses in vivo. It binds to OX40 on T lymphocytes and stimulates the appropriate expansion and/or survival of T cells, leading to IL-4 and IL-13 production (Jenkins et al. 2007, Blazquez & Berin 2008). Here we observed that the immature DCs expressed OX40L in culture and that this expression was downregulated as infection progressed in both viral infections. These data are informative with respect to Th-1/Th-2 axis determination by surface markers on DCs after flavivirus infection. CD38 upregulation and OX40L downregulation indicate that both viruses favour a Th-1 type response during the early immune response, which likely plays a role in virus clearance, although a Th-2 response may be present as well during infections by both viruses (Bozza et al. 2008, Querec et al. 2009).
Indeed, Th-1/Th-2 mixed cytokine patterns, in which an early Th-1 profile gives rise to a late Th-2-predominant pattern, likely occur during the course of a dengue fever infection (Chaturvedi et al. 2000, Mustafa et al. 2001, Nguyen et al. 2004). The difference in timing of IFN-Γ peaks in plasma have influences the severity of disease. On the other hand, reports of an association between low T-bet mRNA expression and high IL-10 levels may indicate a Th-2 role in the pathogenesis of dengue hemorrhagic fever (Chen et al. 2005). YF17DD vaccination leads to a mixed pro/anti-inflammatory cytokine profile, including TNF+ monocytes, IFN-Γ+ NK cells and IL-10+ cells (Silva et al. 2011).
Infection of DCs by DENV induces T cells to produce IL-4, IL-10 and IFN-Γ, suggesting a mixed Th cytokine pattern (Ho et al. 2004). DCs infected with YF17DD stimulate CD8+ T cells from YF17DD-immunised or naive donors and induce IFN-Γ and present antigen specifically to CD8+ and CD4+ T cells (Barba-Spaeth et al. 2005). In the present study, DC cultures infected with flaviviruses were able to produce a panel of several cytokines and chemokines, which were similar in both viral infections. It is likely that chemokines produced by DCs after flavivirus infections, such as IP-10, RANTES and MCP-1, might be signalling to monocytes, NK cells and Th-1 type lymphocytes, resulting in modulation of endothelial permeability, chemotaxis to the site of inflammation, migration to inflammatory sites and T cell polarisation (Aliberti et al. 2000, Thomsen et al. 2003, Nightingale et al. 2008). These cell subsets are crucial for viral clearance and efficient immunological response generation, but we cannot exclude the possibility that an excessive inflammatory reaction may result in exacerbation of disease severity.
The most striking differences between the DENV2 and YF17DD viruses were found in TNF-α and IFN-α production by DCs. TNF-α levels are significantly increased after DENV2 infection in DC cultures, but only slightly altered in the presence of YF17DD and YF17D/DENV2. On the other hand, these viruses were able to elicit high IFN-α levels that not reached during DENV2 infection.
TNF-α is a pro-inflammatory cytokine that has often been found in patients with acute dengue fever and high levels are associated with haemorrhagic manifestations (Hober et al. 1993, Kubelka et al. 1995, Braga et al. 2001, Chakravarti & Kumaria 2006). Together with IL-1β, TNF-α is known to increase acute phase protein production and act in synergy with other factors to induce microbicidal activity during phagocytosis (Clark 2007). It also has the capacity to induce the upregulation of endothelial adhesion molecules, which in turn signal to chemotactic peptides and lipid mediators and facilitate leukocyte recruitment, which may result in plasma leakage and hypovolemic shock. In our in vitro infection model, we observed markedly higher TNF-α production after infection with pathogenic virus (DENV2) as compared to the non-pathogenic viruses (YF17DD and YF17D/DENV2), providing further evidence that this cytokine plays a role in flavivirus immunopathogenesis. Other authors have also observed TNF-α production in DC or monocyte cultures in the presence of DENV2 and some authors even associate it with the infected cell (Hacker et al. 1998, Querec et al. 2006, Deauvieau et al. 2007, Reis et al. 2007, Ahmad et al. 2008, Nightingale et al. 2008, Levy et al. 2009). A moderate level of TNF-α production may be beneficial to mature cells that may become good antigen presenters. This cytokine was detected in YF vaccinated individuals (Roers et al. 1994, Querec et al. 2006, Deauvieau et al. 2007, Levy et al. 2009, Silva et al. 2011).
IFNs are classically known as antiviral molecules and some reports confirm that flaviviruses are susceptible to these molecules (Roers et al. 1994, Diamond et al. 2000). Indeed, these viruses stimulate IFN-α production (Libraty et al. 2001, Deauvieau et al. 2007, Palmer et al. 2007, Querec et al. 2009), although IFN-α induction was not compared between viruses in previous reports. Earlier studies show that DENV is able to escape IFN action by inhibiting steps of IFN type I activation pathways through a decrease in the signal transducer and activator of transcription-2 expression (STAT-2) (Jones et al. 2005). This effect is meditated by the viral non-structural protein 4. Recently, low levels of IFN-α/β production by DENV2-infected MoDCs has been reported as playing a role in the failure of DCs to prime T cells (Rodriguez-Madoz et al. 2010).
In Fig. 7, we outline a theoretical model for flavivirus interactions with DCs. Flavivirus infection may trigger differential signalling pathways that lead to an early clearance of virus. These pathways might include an IFN pathway that activates IFN- regulatory gene (IRF)-7 and IFN-stimulated response element (ISRE), which in turn further induces high IFN-α and nitric oxide production. Alternatively, the blockage of antiviral pathways, such as STAT activation by non-structural viral proteins, may lead to higher virus load and intense stimulation of inflammatory/pathologic mechanisms such as TNF-α. The IFN-α produced by target cells may act on IFN-α receptors on bystander cells to protect them from further infections. Furthermore, IFN-α activates natural killer cells, which have cytotoxic and antiviral functions and produce IFNs that in turn can activate monocytes to exert antiviral functions through nitric oxide production.
Here we observed that DCs infected with YF17DD and YF17D/DENV2 produce more IFN-α than those infected with DENV2. These data suggest that the vaccine viruses may have different virulent properties than DENV2 and that they may have lost (or never acquired) the ability to inhibit the ISRE pathway that was hypothesised to play a role in DENV infection in Fig. 7. YF vaccination in human subjects studied by microarray analysis showed a response profile related to IFN-based antiviral responses (Scherer et al. 2007, Querec et al. 2009), suggesting a role for IFNs in effective protection from this vaccine. On the other hand, functional genetic studies identified several transcripts for IFN-stimulated genes in patients with dengue fever that were less abundant in adults with dengue shock syndrome, reinforcing the attenuating role of IFNs after infection (Simmons et al. 2007). Vaccine or therapeutic approaches may indeed provide the ability to induce antiviral molecules such as IFNs without inducing or modulating factors involved in vascular permeability.
To Denise Cerqueira, Lidiane Martins de Albuquerque and Luciana Gomes Fialho, for their technical collaboration, suggestions and encouragement.
Ahmad SM, Haskell MJ, Raqib R, Stephensen CB 2008. Men with low vitamin A stores respond adequately to primary yellow fever and secondary tetanus toxoid vaccination. J Nutr 138: 2276-2283. [ Links ]
Aliberti J, Reis e Sousa C, Schito M, Hieny S, Wells T, Huffnagle GB, Sher A 2000. CCR5 provides a signal for microbial induced production of IL-12 by CD8 alpha+ dendritic cells. Nat Immunol 1: 83-87. [ Links ]
Assuncao-Miranda I, Amaral FA, Bozza FA, Fagundes CT, Sousa LP, Souza DG, Pacheco P, Barbosa-Lima G, Gomes RN, Bozza PT, Da Poian AT, Teixeira MM, Bozza MT 2010. Contribution of macrophage migration inhibitory factor to the pathogenesis of dengue virus infection. FASEB J 24: 218-228. [ Links ]
Azeredo EL, Zagne SM, Santiago MA, Gouvea AS, Santana AA, Neves-Souza PC, Nogueira RM, Miagostovich MP, Kubelka CF 2001. Characterisation of lymphocyte response and cytokine patterns in patients with dengue fever. Immunobiology 204: 494-507. [ Links ]
Bae HG, Domingo C, Tenorio A, de Ory F, Munoz J, Weber P, Teuwen DE, Niedrig M 2008. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. J Infect Dis 197: 1577-1584. [ Links ]
Barba-Spaeth G, Longman RS, Albert ML, Rice CM 2005. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J Exp Med 202: 1179-1184. [ Links ]
Blanco P, Palucka AK, Pascual V, Banchereau J 2008. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev 19: 41-52. [ Links ]
Blazquez AB, Berin MC 2008. Gastrointestinal dendritic cells promote Th2 skewing via OX40L. J Immunol 180: 4441-4450. [ Links ]
Bozza FA, Cruz OG, Zagne SM, Azeredo EL, Nogueira RM, Assis EF, Bozza PT, Kubelka CF 2008. Multiplex cytokine profile from dengue patients: MIP-1beta and IFN-gamma as predictive factors for severity. BMC Infect Dis 8: 86. [ Links ]
Braga ELA, Moura P, Pinto LMO, Ignacio SRN, Oliveira MJC, Cordeiro MT, Kubelka CF 2001. Detection of circulant tumor necrosis factor-alpha, soluble tumor necrosis factor p75 and interferon-gamma in Brazilian patients with dengue fever and dengue hemorrhagic fever. Mem Inst Oswaldo Cruz 96: 229-232. [ Links ]
Caufour PS, Motta MC, Yamamura AM, Vazquez S, Ferreira I, Jabor AV, Bonaldo MC, Freire MS, Galler R 2001. Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses. Virus Res 79: 1-14. [ Links ]
Chakravarti A, Kumaria R 2006. Circulating levels of tumour necrosis factor-alpha & interferon-gamma in patients with dengue & dengue haemorrhagic fever during an outbreak. Indian J Med Res 123: 25-30. [ Links ]
Chaturvedi UC, Agarwal R, Elbishbishi EA, Mustafa AS 2000. Cytokine cascade in dengue hemorrhagic fever: implications for pathogenesis. FEMS Immunol Med Microbiol 28: 183-188. [ Links ]
Chen LC, Lei HY, Liu CC, Shiesh SC, Chen SH, Liu HS, Lin YS, Wang ST, Shyu HW, Yeh TM 2006. Correlation of serum levels of macrophage migration inhibitory factor with disease severity and clinical outcome in dengue patients. Am J Trop Med Hyg 74: 142-147. [ Links ]
Chen RF, Liu JW, Yeh WT, Wang L, Chang JC, Yu HR, Cheng JT, Yang 2005. Altered T helper 1 reaction but not increase of virus load in patients with dengue hemorrhagic fever. FEMS Immunol Med Microbiol 44: 43-50. [ Links ]
Clark IA 2007. How TNF was recognized as a key mechanism of disease. Cytokine Growth Factor Rev 18: 335-343. [ Links ]
Clyde K, Kyle JL, Harris E 2006. Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J Virol 80: 11418-11431. [ Links ]
Deauvieau F, Sanchez V, Balas C, Kennel A, Dem A, Lang J, Guy B 2007. Innate immune responses in human dendritic cells upon infection by chimeric yellow-fever dengue vaccine serotypes 1-4. Am J Trop Med Hyg 76: 144-154. [ Links ]
Delespesse G, Ohshima Y, Yang LP, Demeure C, Sarfati M 1999. OX40-mediated cosignal enhances the maturation of naive human CD4+ T cells into high IL-4-producing effectors. Int Arch Allergy Immunol 118: 384-386. [ Links ]
Diamond MS, Roberts TG, Edgil D, Lu B, Ernst J, Harris E 2000. Modulation of dengue virus infection in human cells by alpha, beta and gamma interferons. J Virol 74: 4957-4966. [ Links ]
Duangchinda T, Dejnirattisai W, Vasanawathana S, Limpitikul W, Tangthawornchaikul N, Malasit P, Mongkolsapaya J, Screaton G 2010. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci USA 107: 16922-16927. [ Links ]
Fedele G, Frasca L, Palazzo R, Ferrero E, Malavasi F, Ausiello CM 2004. CD38 is expressed on human mature monocyte-derived dendritic cells and is functionally involved in CD83 expression and IL-12 induction. Eur J Immunol 34: 1342-1350. [ Links ]
Fink J, Gu F, Ling L, Tolfvenstam T, Olfat F, Chin KC, Aw P, George J, Kuznetsov VA, Schreiber M, Vasudevan SG, Hibberd ML 2007. Host gene expression profiling of dengue virus infection in cell lines and patients. PLoS Negl Trop Dis 1: e86. [ Links ]
Frasca L, Fedele G, Deaglio S, Capuano C, Palazzo R, Vaisitti T, Malavasi F, Ausiello CM 2006. CD38 orchestrates migration, survival and Th1 immune response of human mature dendritic cells. Blood 107: 2392-2399. [ Links ]
Galler R, Marchevsky RS, Caride E, Almeida LF, Yamamura AM, Jabor AV, Motta MC, Bonaldo MC, Coutinho ES, Freire MS 2005. Attenuation and immunogenicity of recombinant yellow fever 17D-dengue type 2 virus for Rhesus monkeys. Braz J Med Biol Res 38: 1835-1846. [ Links ]
Geisbert TW, Jahrling PB 2004. Exotic emerging viral diseases: progress and challenges. Nat Med 10: S110-121. [ Links ]
Green S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Suntayakorn S, Nisalak A, Rothman AL, Ennis FA 999. Elevated plasma interleukin-10 levels in acute dengue correlate with disease severity. J Med Virol 59: 329-334. [ Links ]
Gubler DJ 2002. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21th century. Trends Microbiol 10: 100-103. [ Links ]
Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J 2010. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 28: 632-649. [ Links ]
Hacker UT, Jelinek T, Erhardt S, Eigler A, Hartmann G, Nothdurft HD, Endres S 1998. In vivo synthesis of tumor necrosis factor-alpha in healthy humans after live yellow fever vaccination. J Infect Dis 177: 774-778. [ Links ]
Halstead SB 2007. Dengue. Lancet 370: 1644-1652. [ Links ]
Ho LJ, Shaio MF, Chang DM, Liao CL, Lai JH 2004. Infection of human dendritic cells by dengue virus activates and primes T cells towards Th0-like phenotype producing both Th1 and Th2 cytokines. Immunol Invest 33: 423-437. [ Links ]
Hober D, Poli L, Roblin B, Gestas P, Chungue E, Granic G, Imbert P, Pecarere JL, Vergez-Pascal R, Wattre P 1993. Serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and interleukin-1 beta (IL-1 beta) in dengue-infected patients. Am J Trop Med Hyg 48: 324-331. [ Links ]
Jenkins SJ, Perona-Wright G, Worsley AG, Ishii N, MacDonald AS 2007. Dendritic cell expression of OX40 ligand acts as a costimulatory, not polarizing, signal for optimal Th2 priming and memory induction in vivo. J Immunol 179: 3515-3523. [ Links ]
Jones M, Davidson A, Hibbert L, Gruenwald P, Schlaak J, Ball S, Foster GR, Jacobs M 2005. Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. J Virol 79: 5414-5420. [ Links ]
Khaiboullina SF, Rizvanov AA, Holbrook MR, St Jeor S 2005. Yellow fever virus strains Asibi and 17D-204 infect human umbilical cord endothelial cells and induce novel changes in gene expression. Virology 342: 167-176. [ Links ]
Kubelka CF, Borges PA, VonSydow FF, Farid FO, Lampe E 1995. Analysis of tumor necrosis factor-alpha serum level in Brazilian patients with dengue-2. Mem Inst Oswaldo Cruz 90: 741-742. [ Links ]
Lanzavecchia A, Sallusto F 2004. Lead and follow: the dance of the dendritic cell and T cell. Nat Immunol 5: 1201-1202. [ Links ]
Lee YR, Liu MT, Lei HY, Liu CC, Wu JM, Tung YC, Lin YS, Yeh TM, Chen SH, Liu HS 2006. MCP-1, a highly expressed chemokine in dengue haemorrhagic fever/dengue shock syndrome patients may cause permeability change, possibly through reduced tight junctions of vascular endothelium cells. J Gen Virol 87: 3623-3630. [ Links ]
Leitmeyer KC, Vaughn DW, Watts DM, Salas R, Villalobos I de C, Ramos C, Rico-Hesse R 1999. Dengue virus structural differences that correlate with pathogenesis. J Virol 73: 4738-4747. [ Links ]
Levy A, Valero N, Espina LM, Anez G, Arias J, Mosquera J 2009. Increment of interleukin 6, tumour necrosis factor alpha, nitric oxide, C-reactive protein and apoptosis in dengue. Trans R Soc Trop Med Hyg 104: 16-23. [ Links ]
Libraty DH, Pichyangkul S, Ajariyakhajorn C, Endy TP, Ennis FA 2001. Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis. J Virol 75: 3501-3508. [ Links ]
Martins MA, Silva ML, Eloi-Santos SM, Ribeiro JG, Peruhype-Magalhaes V, Marciano AP, Homma A, Kroon EG, Teixeira-Carvalho A, Martins-Filho OA 2008. Innate immunity phenotypic features point toward simultaneous raise of activation and modulation events following 17DD live attenuated yellow fever first-time vaccination. Vaccine 26: 1173-1184. [ Links ]
Miagostovich MP, Nogueira RM, Cavalcanti SM, Marzochi KB, Schatzmayr HG 1993. Dengue epidemic in the state of Rio de Janeiro, Brazil: virological and epidemiological aspects. Rev Inst Med Trop Sao Paulo 35: 149-154. [ Links ]
Monath TP 2001. Yellow fever: an update. Lancet Infect Dis 1: 11-20. [ Links ]
Mustafa AS, Elbishbishi EA, Agarwal R, Chaturvedi UC 2001. Elevated levels of interleukin-13 and IL-18 in patients with dengue hemorrhagic fever. FEMS Immunol Med Microbiol 30: 229-233. [ Links ]
Neves-Souza PC, Azeredo EL, Zagne SM, Valls-de-Souza R, Reis SR, Cerqueira DI Nogueira RM, Kubelka CF 2005. Inducible nitric oxide synthase (iNOS) expression in monocytes during acute dengue fever in patients and during in vitro infection. BMC Infect Dis 5: 64. [ Links ]
Nguyen TH, Lei HY, Nguyen TL, Lin YS, Huang KJ, Le BL, Lin CF, Yeh TM, Do QH, Vu TQ, Chen LC, Huang JH, Lam TM, Liu CC, Halstead SB 2004. Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. J Infect Dis 189: 221-232. [ Links ]
Nightingale ZD, Patkar C, Rothman AL 2008. Viral replication and paracrine effects result in distinct, functional responses of dendritic cells following infection with dengue 2 virus. J Leuk Biol 84: 1028-1038. [ Links ]
Noisakran S, Perng GC 2008. Alternate hypothesis on the pathogenesis of dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS) in dengue virus infection. Exp Biol Med (Maywood) 233: 401-408. [ Links ]
Ohshima Y, Tanaka Y, Tozawa H, Takahashi Y, Maliszewski C, Delespesse G 1997. Expression and function of OX40 ligand on human dendritic cells. J Immunol 159: 3838-3848. [ Links ]
Ohshima Y, Yang LP, Uchiyama T, Tanaka Y, Baum P, Sergerie M, Hermann P, Delespesse G 1998. OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naÏve human CD4(+) T cells into high IL-4-producing effectors. Blood 92: 3338-3345. [ Links ]
Palmer DR, Fernandez S, Bisbing J, Peachman KK, Rao M, Barvir D, Gunther V, Burgess T, Kohno Y, Padmanabhan R, Sun W 2007. Restricted replication and lysosomal trafficking of yellow fever 17D vaccine virus in human dendritic cells. J Gen Virol 88: 148-156. [ Links ]
Post PR, Santos CND, Carvalho R, Lopes OS, Galler R 1991. Molecular analysis of yellow fever virus 17DD vaccine strain. Mem Inst Oswaldo Cruz 86: 239-246. [ Links ]
Pulendran B, Miller J, Querec TD, Akondy R, Moseley N, Laur O, Glidewell J, Monson N, Zhu T, Zhu H, Staprans S, Lee D, Brinton MA, Perelygin AA, Vellozzi C, Brachman P Jr, Lalor S, Teuwen D, Eidex RB, Cetron M, Priddy F, del Rio C, Altman J, Ahmed R 2008. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses and polymorphisms in CCR5 and RANTES genes. J Infect Dis 198: 500-507. [ Links ]
Quah BJ, O'Neill HC 2005. Maturation of function in dendritic cells for tolerance and immunity. J Cell Mol Med 9: 643-654. [ Links ]
Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, Flavell R, Akira S, Ahmed R, Pulendran B 2006. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8 and 9 to stimulate polyvalent immunity. J Exp Med 203: 413-424. [ Links ]
Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, Pirani A, Gernert K, Deng J, Marzolf B, Kennedy K, Wu H, Bennouna S, Oluoch H, Miller J, Vencio RZ, Mulligan M, Aderem A, Ahmed R, Pulendran B 2009. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10: 116-125. [ Links ]
Reis SRNI, Sampaio ALF, Henriques MGM, Gandini M, Azeredo EL, Kubelka CF 2007. An in vitro model for dengue virus infection that exhibits human monocyte infection, multiple cytokine production and dexamethasone immunomodulation. Mem Inst Oswaldo Cruz 102: 983-990. [ Links ]
Rodriguez-Madoz JR, Bernal-Rubio D, Kaminski D, Boyd K, Fernandez-Sesma A 2010. Dengue virus inhibits the production of type I interferon in primary human dendritic cells. J Virol 84: 4845-4850. [ Links ]
Roers A, Hochkeppel HK, Horisberger MA, Hovanessian A, Haller O 1994. MxA gene expression after live virus vaccination: a sensitive marker for endogenous type I interferon. J Infect Dis 169: 807-813. [ Links ]
Sabatte J, Maggini J, Nahmod K, Amaral MM, Martinez D, Salamone G, Ceballos A, Giordano M, Vermeulen M, Geffner J 2007. Interplay of pathogens, cytokines and other stress signals in the regulation of dendritic cell function. Cytokine Growth Factor Rev 18: 5-17. [ Links ]
Scherer CA, Magness CL, Steiger KV, Poitinger ND, Caputo CM, Miner DG, Winokur PL, Klinzman D, McKee J, Pilar C, Ward PA, Gillham MH, Haulman NJ, Stapleton JT, Iadonato SP 2007. Distinct gene expression profiles in peripheral blood mononuclear cells from patients infected with vaccinia virus, yellow fever 17D virus or upper respiratory infections. Vaccine 25: 6458-6473. [ Links ]
Schnittler HJ, Feldmann H 2003. Viral hemorrhagic fever - a vascular disease? Thromb Haemost 89: 967-972. [ Links ]
Silva ML, Espirito-Santo LR, Martins MA, Silveira-Lemos D, Peruhype-Magalhaes V, Caminha RC, de Andrade Maranhao-Filho P, Auxiliadora-Martins M, de Menezes Martins R, Galler R, da Silva Freire M, Marcovistz R, Homma A, Teuwen DE, Eloi-Santos SM, Andrade MC, Teixeira-Carvalho A, Martins-Filho OA 2010. Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination. Clin Vaccine Immunol 17: 118-126. [ Links ]
Silva ML, Martins MA, Espirito-Santo LR, Campi-Azevedo AC, Silveira-Lemos D, Ribeiro JG, Homma A, Kroon EG, Teixeira-Carvalho A, Eloi-Santos SM, Martins-Filho OA 2011. Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults. Vaccine 29: 583-592. [ Links ]
Simmons CP, Popper S, Dolocek C, Chau TN, Griffiths M, Dung NT, Long TH, Hoang DM, Chau NV, Thao le TT, Hien TT, Relman DA, Farrar J 2007. Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever. J Infect Dis 195: 1097-1107. [ Links ]
Srikiatkhachorn A 2009. Plasma leakage in dengue haemorrhagic fever. Thromb Haemost 102: 1042-1049. [ Links ]
Srikiatkhachorn A, Green S 2010. Markers of dengue disease severity. Curr Top Microbiol Immunol 338: 67-82. [ Links ]
Steinman RM, Nussenzweig MC 2002. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 99: 351-358. [ Links ]
Suharti C, van Gorp EC, Setiati TE, Dolmans WM, Djokomoeljanto RJ, Hack CE, Ten CH, van der Meer JW 2002. The role of cytokines in activation of coagulation and fibrinolysis in dengue shock syndrome. Thromb Haemost 87: 42-46. [ Links ]
Sun P, Fernandez S, Marovich MA, Palmer DR, Celluzzi CM, Boonnak K, Liang Z, Subramanian H, Porter KR, Sun W, Burgess TH 2009. Functional characterization of ex vivo blood myeloid and plasmacytoid dendritic cells after infection with dengue virus. Virology 383: 207. [ Links ]
Thomsen AR, Nansen A, Madsen AN, Bartholdy C, Christensen JP 2003. Regulation of T cell migration during viral infection: role of adhesion molecules and chemokines. Immunology Lett 85: 119-127. [ Links ]
Vasconcelos PF, Luna EJ, Galler R, Silva LJ, Coimbra TL, Barros VL, Monath TP, Rodigues SG, Laval C, Costa ZG, Vilela MF, Santos CL, Papaiordanou PM, Alves VA, Andrade LD, Sato HK, Rosa ES, Froguas GB, Lacava E, Almeida LM, Cruz AC, Rocco IM, Santos RT, Oliva OF 2001. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 358: 91-97. [ Links ]
Wallet MA, Sen P, Tisch R 2005. Immunoregulation of dendritic cells. Clin Med Res 3: 166-175. [ Links ]
Woodson SE, Freiberg AN, Holbrook MR 2011. Differential cytokine responses from primary human Kupffer cells following infection with wild-type or vaccine strain yellow fever virus. Virology 412: 188-195. [ Links ]
Wu SJ, Grouard-Vogel G, Sun W, Mascola JR, Brachtel E, Putvatana R, Louder MK, Filgueira L, Marovich MA, Wong HK, Blauvelt A, Murphy GS, Robb ML, Innes BL, Birx DL, Hayes CG, Frankel SS 2000. Human skin Langerhans cells are targets of dengue virus infection. Nat Med 6: 816-820. [ Links ]
Youn S, Cho H, Fremont DH, Diamond MS 2010. A short N-terminal peptide motif on flavivirus nonstructural protein NS1 modulates cellular targeting and immune recognition. J Virol 84: 9516-9532. [ Links ]
Received 7 February 2011
Accepted 8 June 2011
Financial support: IOC/Bio-Manguinhos/FIOCRUZ, DECICT/CNPq, FAPERJ, ICGEB